Retatrutide vs Amycretin

Retatrutide and Amycretin represent distinct approaches to multi-receptor agonism in metabolic research. Retatrutide, developed by Eli Lilly, functions as a triple agonist targeting GIP, GLP-1, and glucagon receptors, benefiting from a robust Phase 2 evidence base and ongoing Phase 3 trials. In contrast, Amycretin, from Novo Nordisk, is a dual GLP-1/amylin receptor co-agonist, notable for its oral bioavailability as a peptide. Both compounds are being investigated for obesity and related metabolic conditions, but their mechanisms, dosing regimens, and safety profiles differ substantially. This comparison highlights key distinctions to guide researchers in selecting the appropriate tool for their studies.

Retatrutide is a pioneering triple hormone receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors, aiming to leverage the synergistic effects of these pathways on metabolism. In the pivotal Phase 2 trial conducted by Jastreboff et al. (NEJM 2023, n=338), participants receiving a 12 mg dose experienced an impressive mean body weight reduction of 24.2% over 48 weeks, with all participants achieving at least a 5% weight loss. This outcome is among the highest reported for investigational peptides in obesity research, underscoring its potential impact. Ongoing Phase 3 TRIUMPH trials, particularly TRIUMPH-4 (data anticipated December 2025), are expected to provide further insights, with preliminary results indicating average weight loss of up to 71.2 lbs and improvements in osteoarthritis-related pain. Additionally, Retatrutide has shown promise in enhancing glycemic control in type 2 diabetes, suggesting its applicability across a broader spectrum of metabolic disorders.

Amycretin is a novel unimolecular peptide co-agonist that simultaneously activates GLP-1 and amylin receptors, aiming to exploit their synergistic effects to improve appetite regulation and energy homeostasis. Developed by Novo Nordisk, Amycretin is particularly noteworthy for its oral formulation, which addresses the common bioavailability issues associated with peptide therapeutics. The Phase 2 REDEFINE 1 trial demonstrated that oral Amycretin achieved up to 13.1% body weight loss at 36 weeks, a significant finding for an oral peptide. This positions Amycretin distinctively against small-molecule oral GLP-1 agonists, as it retains its peptide structure while engaging dual receptors. A subcutaneous formulation is also under investigation, with Phase 3 trials expected to begin in 2026. Early data suggest that the dual agonism may confer differentiated efficacy and tolerability, warranting further exploration in forthcoming studies.

Both Retatrutide and Amycretin are primarily investigated for their roles in metabolic health, particularly in obesity and weight management. Retatrutide's research encompasses not only weight management but also its effects on body composition and glycemic control in type 2 diabetes. Conversely, Amycretin is primarily focused on weight loss and obesity treatment, with a notable emphasis on its oral delivery, which may enhance patient compliance. While both compounds share overlapping research applications, their distinct receptor targets—triple agonism for Retatrutide versus dual agonism for Amycretin—may lead to varying downstream effects on energy expenditure, satiety, and metabolic rate. These nuances are critical for researchers to consider when designing studies aimed at exploring specific metabolic pathways or therapeutic endpoints.

The safety profile of Retatrutide has been characterized by dose-dependent gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, with incidence rates ranging from 13% to 63% across different dose groups in Phase 2 trials. Most of these events were classified as mild to moderate and were somewhat alleviated by starting treatment at a lower initial dose (2 mg vs. 4 mg). Additionally, a dose-dependent increase in heart rate was observed, peaking at 24 weeks before declining. For Amycretin, the predominant adverse events also involve gastrointestinal symptoms—nausea, vomiting, and diarrhea—consistent with effects typically seen in GLP-1 receptor agonists. In a Phase 1 trial (Gasiorek et al., Lancet 2025), these effects were mainly mild to moderate and occurred primarily during dose escalation, diminishing with ongoing treatment. Both peptides necessitate careful dose titration to manage tolerability, although the specific patterns of adverse events differ.